1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68ED703A1AB3439B585257D8700744968
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-digital-marketing-excellence-investment-return-on-investment-benchmarks?opendocument
18
19opendocument
2035.172.150.239
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Marketing Management Digital Marketing

Digital Marketing Excellence: Investment and Return on Investment Benchmarks

ID: 5335


Features:

14 Info Graphics

21 Data Graphics

350+ Metrics

4 Narratives


Pages/Slides: 44


Published: 2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Digital Marketing Investment Excellence: Investment and Return on Investment Benchmarks"

STUDY OVERVIEW

Like other industry sectors, the pharmaceutical industry recognizes the important role Digital Marketing plays in engaging customers. As the role and impact of Digital Marketing continues to grow, pharma wants to ensure it not only is appropriately funding its Digital Marketing teams but also is maximizing its customer impact and return on investment.

Best Practices, LLC conducted this study to capture budgetary benchmarks on how leading Digital teams optimize resource investment across key channels to maximize customer impact and return on investment

In particular, this research contains current and forecasted investment levels, Digital Marketing investments as a percentage of total marketing budget, investment across key DM channels & activities and the impact of digital activities on customers & ROI measurement

This study provides segment perspectives on large, mid-cap and small companies as well as global vs. U.S.-only companies.


KEY TOPICS

  • Study Overview
  • Key Findings & Trends
  • Digital Marketing Investment Levels & Trends
  • Measuring Digital Impact & Return on Investment

SAMPLE KEY METRICS
  • Organization's total Digital Marketing budget for current and next fiscal years
  • Organization's total Digital Marketing budget allocated per FTE for current and next fiscal years
  • Percentage of organization's total marketing budget allocated to Digital Marketing
  • Percentage of total Digital budget allocated to the following (12) key Digital Marketing activities
  • Which Digital activities have the greatest impact on engaging and influencing customers
  • Degree of ROI able to show for the following (17) Digital activities
SAMPLE KEY FINDINGS
  • Large Pharma DM Teams Allot 51% of Budget to Websites & iPads Alone: Digital teams within large pharma concentrate resources into just a few areas, including websites (28%), iPad support (23%), and miscellaneous activities (10%). Mid-cap investment appears more balanced overall, with iPads (22%), mobile optimization (16%), email (14%), websites (9%), social media, analytics, and miscellaneous activities all garnering at least 8% of budget.
  • US Teams Are Budgeting Heavily for New Digital Marketing Opportunities: From a budget perspective, global teams appear more reliant on high-leverage activities like website development, iPad rollout, and email marketing (combined 54% of total budget) than do their US-only competitors focused on a single market. US teams invest more in content development, direct online customer engagement, and roughly 22% of remaining budget to other specialized opportunity areas.

METHODOLOGY

Best Practices, LLC engaged 48 Digital Marketing leaders at 42 companies through a benchmarking survey instrument. Representatives from 8 companies participated in deep-dive interviews.


Industries Profiled:
Pharmaceutical; Health Care; Diagnostic; Manufacturing; Biotech; Consumer Products; Medical Device; Biopharmaceutical; Clinical Research; Laboratories; Marketing


Companies Profiled:
Teva Pharmaceutical Industries Ltd; Abbott; Abbvie; Merck; Bayer; Sanofi; Pfizer; Takeda Pharmaceuticals; Boehringer Ingelheim; Roche; Amgen; GlaxoSmithKline ; Novo Nordisk; Covidien; LEO Pharma; Biogen Idec; Olympus Corporation; Eisai; Mylan; UCB Pharma; Ferring Pharmaceuticals; Lundbeck; Catalent Pharma Solutions; Astellas; CSL Behring; Ranbaxy; Galderma; Chiesi; Boston Scientific; Edwards Lifesciences; Purdue Pharma; Nektar Therapeutics; Merial; Triplefin; biokit; Precision Therapeutics; Genomic Health; Meridian Bioscience; Vivus; Cochlear; Haemonetics Corporation; MD Outlook

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.